anti-CD3/CD38 bispecific monoclonal antibody IGM-2644

{
  "id": "MLC-T-ONC-010382",
  "term": "anti-CD3/CD38 bispecific monoclonal antibody IGM-2644",
  "field": "Oncology and biomedicine",
  "definition": "An engineered bispecific, pentameric immunoglobulin M (IgM) monoclonal antibody directed against CD3, a T-cell surface antigen, and CD38, a human cell surface glycoprotein and tumor-associated antigen (TAA), with potential antineoplastic activity. IGM-2644 consists of ten CD38 binding sites and an anti-CD3epsilon single chain variable fragment (scFv) domain fused to a joining chain. Upon intravenous administration, anti-CD3/CD38 bispecific monoclonal antibody IGM-2644 targets and binds to both CD3 on T cells and CD38 expressed on tumor cells. The resulting cross-linkage may trigger T-cell dependent cellular cytotoxicity (TDCC) and complement-dependent cytotoxicity (CDC) against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.",
  "synonyms": [
    "anti-CD3/anti-CD38 monoclonal antibody IGM-2644",
    "anti-CD3/CD38 monoclonal antibody IGM-2644",
    "CD38xCD3 bispecific T cell engager IGM-2644",
    "TCE IGM-2644"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-cd3-cd38-bispecific-monoclonal-antibody-igm-2644/"
}